How Rutgers is using big data to fight fast moving cancers

Cancer is a disease that attacks the body from the inside.  Science is advancing daily to help doctors and researcher pinpoint and target the specific types of cancers, but how can this be done in a timely manner to help the patients get proper treatment in the right amount of time?  At Rutgers Today, Michele Fisher and Carl Blesch look at how The Rutgers Cancer Institute and Rutgers Discovery Informatics Institute (RDI2) are teaming up to analyze genomes and human tissues to detect where the cancer will go before it's too late for the patient.

According to the article:
Data crunching and analytics expertise provided by RDI2, and biomaterials and technical support from RUCDR Infinite Biologics – coupled with evaluation by a team of scientific, clinical and bioinformatics experts at the Cancer Institute – are shaping a revolution in how best to determine therapy – a vast improvement over the time-intensive, trial-and-error approach that clinicians have faced for years.

Rutgers is also taking on the cancers many others are hesitant to touch - from ovarian cancers to pancreatic cancers to certain pediatric cancers.

This fall at the BioProcess International Event, Ganesh V. Kaundinya, Ph.D., Co-Founder and Chief Scientific Officer, Momenta Pharmaceuticals will be on hand to examine this topic further in the presentation Understanding Complexity in Biological Systems through Big Data Analytics- Applications to Biosimilars and Novel Biologics.  For more information on this session and the rest of the program, download the brochure. If you'd like to join us October 20-23 in Boston, as a reader of this blog, you can register to join us with priority code BPI14BLOG and you can save 20% off the standard rate!

Are there any other partnerships standing out to you where big data and scientists are joining forces to treat fast moving cancers or other illnesses?

Share this article with your social network, just click below to share now!

Share |